قالب وردپرس درنا توس
Home / Insurance / Cannabis tests can be complex, inaccurate

Cannabis tests can be complex, inaccurate



Testing for reduced marijuana is one of the major challenges posed by a state decriminalization of cannabis use for adults.

Unlike alcohol, for which both standards and a technical solution exist in the form of the breathalyzer, testing for the presence or deterioration of cannabis is more complex.

“It’s not just a breathalyzer like with alcohol, a simple test. With cannabis it’s a urine test. It’s a much more invasive way to test and it’s not immediate,” said Mark Turkalo, head of national education and public services for Marsh LLC in New York.

There is also evidence that cannabis differs from alcohol in terms of disability.

The National Institute of Justice, part of the US Department of Justice, supported researchers from RTI International, a non-profit research organization, to study how levels of tetrahydrocannabinol ̵

1; which produces “high” cannabis – in the body correlate with performance in disability tests and concluded that THC- levels in bio fluids were not reliable indicators of marijuana poisoning for study participants.

The researchers reported that one leg was standing, walking and turning and the balance tests were not sensitive to cannabis poisoning for any of the study participants.

A study from the University of Sydney from December 2021, which analyzed available studies on the relationship between driving performance and blood concentrations and saliva of THC, showed results that indicate that THC concentrations in blood and oral fluid are relatively poor or inconsistent indicators of cannabis-induced disability. .

“Higher THC concentrations in the blood were only weakly associated with increased impairment in individual cannabis users while no significant association was detected in regular cannabis users. This indicates that THC concentrations in blood and oral fluid are relatively poor indicators of cannabis-THC-induced impairment. says the study’s lead author Danielle McCartney of the Lambert Initiative for Cannabinoid Therapeutics.

The lack of both rapid testing technology and a reliable standard that defines disability may mean that effective testing is still a long way off, says Paul Shives, vice president of security services, with JA Montgomery Consulting in Parsippany, New Jersey. “It will take a while,” he said.


Source link